CD8A and breast cancer: Therapeutics capable of augmenting CTL density within the TME would be expected to promote a more effective anti-tumor immune response, as high baseline CTL (CD8+) density are associated with chemosensitivity across BC subtypes and improved survival in TNBC and HER2 amplified BC (3, 21).